搜索
Biogen Inc
BIIB添加自选
199.590USD
+2.400+1.22%
收盘 06/24, 16:00（美东）报价延迟15分钟
29.47B总市值
21.35市盈率 TTM
关于 Biogen Inc 公司
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Biogen Inc简介
公司代码BIIB
公司名称Biogen Inc
上市日期Sep 17, 1991
CEOViehbacher (Christopher A)
员工数量7605
证券类型Ordinary Share
年结日Sep 17
公司地址225 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02142
电话17814642000
网址https://www.biogen.com/
公司代码BIIB
上市日期Sep 17, 1991
CEOViehbacher (Christopher A)
Biogen Inc公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.89K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
27.84K
-4.94%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.10K
+20.79%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
19.75K
+0.69%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
16.08K
+30.17%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.82K
+11.74%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.89K
+16.92%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
8.04K
-0.01%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
6.45K
+31.09%
Dr. Adam James Keeney, Ph.D.
Dr. Adam James Keeney, Ph.D.
Executive Vice President, Head of Corporate Development
Executive Vice President, Head of Corporate Development
6.37K
+7.60%
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
61.89K
--
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
27.84K
-4.94%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
22.10K
+20.79%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
19.75K
+0.69%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
16.08K
+30.17%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.82K
+11.74%
常见问题
Biogen Inc的前五大股东是谁？
Biogen Inc 的前五大股东如下：Ms. Susan H. Alexander, Esq., J.D.
有多少机构持有Biogen Inc(BIIB)的股份？
截至2026Q1，共有2085家机构持有Biogen Inc的股份，合计持有的股份价值约为144.76M，占公司总股份的98.05%。与2025Q4相比，机构持股有所增加，增幅为-3983853.00。
哪个业务部门对Biogen Inc的收入贡献最大？
在2026Q1，Spinal Muscular Atrophy-SPINRAZA业务部门对Biogen Inc的收入贡献最大，创收2.15B，占总收入的21.78%。
